Results 131 to 140 of about 2,201,777 (199)

TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response. [PDF]

Hereditas
Chen N, Wang T, Li Y, Zhang R, Wei X, Wang Z.   +5 more
europepmc   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model. [PDF]

Cancer Sci
Tanaka T, Fujitani M, Taoka M, Shimomura I, Okawa S, Mori S, Kuribayashi T, Nishimura J, Nishimura T, Morita A, Hara N, Ninomiya K, Makimoto G, Higo H, Rai K, Ichihara E, Tomida S, Hotta K, Togashi Y, Maeda Y, Kiura K, Katayama R, Ohashi K.   +22 more
europepmc   +1 more source

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC. [PDF]

Cell Death Dis
Armanetti P, Cabrera San Millan E, Di Nardo M, Mercatelli R, Cavallini C, Crucitta S, Del Re M, Chiodi A, Mosca E, Consiglio A, Losito N, Musio A, Menichetti L, Bramanti E, Ali A, Levantini E, Maroni G.   +16 more
europepmc   +1 more source

Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling. [PDF]

Am J Cancer Res
Mhone TG, Kuo WW, Chi CY, Kuo CH, Ho TJ, Wu YL, Lin YM, Chen MC, Huang CY, Lin SZ.   +9 more
europepmc   +1 more source

Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer [PDF]

Journal of Thoracic Oncology, 2017
D. Westover, H. Qiao, E. Ichihara, C.B. Meador, C.M. Lovly   +4 more
openaire   +1 more source

USP7-dependent stabilization of FKBP4 contributes to acquired osimertinib resistance through glycolytic remodeling in NSCLC. [PDF]

Sci Rep
Pang W, Fang M, Wu W.
europepmc   +1 more source

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma. [PDF]

ESMO Open
Ibusuki R, Iwama E, Shimauchi A, Kawano H, Tsuneoka Y, Hashisako M, Harada T, Tsuchiya-Kawano Y, Nakatomi K, Furuyama K, Nakagaki N, Koga Y, Kimura S, Mashimoto S, Shibahara D, Otsubo K, Yoneshima Y, Shiraishi Y, Tanaka K, Oda Y, Okamoto I.   +20 more
europepmc   +1 more source

A Non-Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non-Small Cell Lung Cancer. [PDF]

Adv Sci (Weinh)
Liu A, Liu Z, Jiang L, Huang A, Lin X, Li X, Liu B, Hu S, Pan Q, Huang J, Yin L, Jiang L, Yi W, Mao W, Zheng Y, Shi X.   +15 more
europepmc   +1 more source

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy [PDF]

Journal of Thoracic Oncology, 2019
Yihua Huang, Jiadi Gan, Kunbin Guo, Yangyang Deng, Wenfeng Fang   +4 more
openaire   +1 more source

Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance. [PDF]

Front Oncol
Song S, Yao D, Liu J, Nie W, He M, Zhang J, Zhao J.   +6 more
europepmc   +1 more source